Spinocerebellar ataxia (SCA) is characterized clinically by progressive ataxia attributed to various etiologies. Ataxia is a complaint of loss of control of voluntary body movements and can involve unsteady gait, speech difficulties, and clumsiness, potentially progressing to the stage of difficulty with swallowing and breathing due to degenerative changes in the brain and spinal cord.
There is no cure for the hereditary SCAs and lifespan can be significantly shortened due to complications related to neurologic deficits. It is estimated that 150,000 people in the United States are affected by hereditary ataxias. Treatment is supportive and no medications are currently approved for this potentially debilitating condition.
BHV-0223 is a unique formulation of riluzole, a glutamate modulating agent, that utilizes the Zydis ODT fast-dissolve technology under an exclusive worldwide agreement with Catalent.
Agents that modulate glutamate neurotransmission may have therapeutic potential in multiple disease states involving glutamate dysfunction, including ALS, Alzheimer’s disease, Rett syndrome, dementia, dystonia, tinnitus, anxiety disorders, and affective disorders like major depressive disorder. Biohaven is pursuing the use of glutamate modulating agents across several therapeutic indications.
"Modulation of cerebellar glutamate has potential for efficacy in populations with spinocerebellar ataxias, Biohaven sees an opportunity to leverage its glutamate targeting drug platform to address this important debilitating illness," commented Robert Berman, M.D., CMO of Biohaven.
Vlad Coric, M.D., CEO of Biohaven, added, "Receiving the orphan drug designation request for spinocerebellar ataxia supports our global development strategy and goal of providing improved therapies for patients suffering from neurologic disorders with unmet need."
Before the end of 2016, Biohaven expects to initiate a randomized clinical trial of its new chemical entity (NCE) glutamate modulating agent in patients with spinocerebellar ataxia. The study will enroll approximately 120 patients in the U.S. and will evaluate acute symptomatic treatment in this patient population. The trial is expected to support a New Drug Application (NDA) in SCA.
FDA orphan drug designation is intended to encourage companies to develop therapies for the treatment of diseases that affect fewer than 200,000 individuals in the United States. This designation will provide Biohaven with 7 years of marketing exclusivity for BHV-0223 if approved by the FDA in such indication. Prior to FDA approval, orphan designation by the FDA provides the opportunity to obtain clinical trial tax credits for research, grant funding to defray development costs, and potential waiver of the FDA’s application user fees.
Grey Bailey, Chairman of Portage commented, "This is a significant step in the development of the Biohaven portfolio". He also emphasized the importance of this for Portage shareholders."